Funding for this research was provided by:
National Cancer Institute (R01 CA218802, F30 CA180607, P30 CA006927, R21 CA223394-01A1)
Received: 11 October 2018
Accepted: 5 June 2019
First Online: 19 June 2019
Ethics approval and consent to participate
: The protocol for this study was approved by the Fox Chase Cancer Center (FCCC) Institutional Review Board (IRB), study number 10–043. Nanostring mRNA expression analysis was additionally covered by the FCCC IRB, study number 18–4002. Informed consent was obtained from patients.
: Not applicable.
: Y.B. has served on advisory boards of Astra Zeneca, AbbVie and Caris Life Sciences. YB. Is also an Editorial Board member for <i>BMC Cancer</i>. C.A. has served on advisory boards of Genentech and Celgene. R. M. has served as a consultant for Genentech and on advisory board of Bristol-Meyers Squibb. H. B. has received research support for clinical trials from Millennium, Merck/Celgene, BMS/Lilly, has served on advisory board or as a consultant for BMS, Lilly, Genentech, Celgene, Pfizer, Merck, EMD-Serono, Boehringer Ingelheim, Astra Zeneca, Novartis, Genmab, Regeneron, BioNTech, Cantargia AB, Amgen, Abbvie, Axiom, PharmaMar, and on data and safety monitoring board for the University of Pennsylvania, CAR T Program. M.C. has served on advisory boards of Vortex, Dompe, and received research support from Pfizer and honoraria from Pfizer. The authors have no other conflicts to disclose.